Typ : |
Labor |
|
Forschungsgruppen : |
|
Autoren : |
|
Titel : |
Atezolizumab (Tecentriq®) - Summary of Product Characteristics |
Veröffentlichung : |
Roche Products Limited 2021 |
|
Niveau von Beweisen : |
|
Physikalische Stabilität : |
|
Chemische Stabilität : |
|
Andere Verfahren : |
|
Kommentare : |
|
Molekülverzeichnis
Atezolizumab
|
|
|
|
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
24 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
24 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
24 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
24 |
|
|
|
|
|